Skip to main content

Table 3 Efficacy of CAG in newly diagnosed, relapsed and refractory AML

From: A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

Study (ref)

Year

Newly diagnosed AML

R/R AML

  

No.

Patients

CR No.

CR %

No.

Patients

CR No.

CR %

Yamada [14]

1995

NA

NA

NA

18

15

83

Saito [35]

1995

NA

NA

NA

18

15

83

Saito [36]

1996

NA

NA

NA

28

24

86

Tabata [37]

1998

8

5

63

NA

NA

NA

Saito [38]

2000

8

5

63

43

30

70

Hirayama [39]

2003

9

6

67

NA

NA

NA

Li [26]

2005

NA

NA

NA

80

38

47

Kong [40]

2005

20

11

55

NA

NA

NA

Yang [41]

2005

16

9

56

NA

NA

NA

Xie [42]

2006

25

12

48

NA

NA

NA

Wang [43]

2006

NA

NA

NA

11

4

36

Wu [44]

2007

15

8

53

NA

NA

NA

Qian [20]

2007

35

23

66

12

5

40

Guo [45]

2007

NA

NA

NA

8

4

50

Chen [46]

2008

34

23

68

NA

NA

NA

Sang [47]

2008

23

9

39

NA

NA

NA

Bian [48]

2008

NA

NA

NA

26

20

77

Chai [49]

2009

NA

NA

NA

17

8

47

Zhu [50]

2009

NA

NA

NA

30

14

46

Ni [51]

2009

27

19

70

34

15

44

Feng [52]

2010

16

9

56

NA

NA

NA

Ma [28]

2010

NA

NA

NA

11

6

55

Li [53]

2010

NA

NA

NA

18

14

78

Liang [54]

2010

23

14

61

16

7

44

Suzushima [55]

2010

68

33

49

NA

NA

NA

  1. Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; Ref: references; NA: not available; m: month; CR: complete remission; OS: overall survival; CAG: cytarabine, aclarubicin and G-CSF.